Biosimilar Lantus is causing rivals to cut prices to compete
Label will reflect heart benefit seen in LEADER trial.
Lower severe hypo risk compared with Lantus – but no cardiac benefit.
An innovative programme is being rolled out across Kenya.
Sanofi under pressure following long-awaited biosimilar launch.
President-elect takes swipe at pharma after Time “Person of the Year” accolade.